First-line Sunitinib, Pazopanib Have Similar Efficacy for mRCC in Population-based Setting

Share this content:
In a population-based setting, sunitinib and pazopanib have similar efficacy in the first-line treatment of patients with metastatic renal cell carcinoma.
In a population-based setting, sunitinib and pazopanib have similar efficacy in the first-line treatment of patients with metastatic renal cell carcinoma.

MIAMI—In a population-based setting, sunitinib and pazopanib have similar efficacy in the first-line treatment of patients with metastatic renal cell carcinoma (mRCC), a study presented at the 14th International Kidney Cancer Symposium (IKCS) has shown.1

Although sunitinib and pazopanib were compared in patients with mRCC in the head-to-head phase 3 COMPARZ study,2 researchers sought to compare first-line sunitinib with pazopanib in a population-based setting in order to confirm treatment outcomes.

For the study, researchers analyzed data from 3606 patients with mRCC treated with either first-line sunitinib or pazopanib who were included in the International mRCC Database Consortium (IMDC). Of those, 3226 received sunitinib while 380 received pazopanib. The overall median follow-up was 43.5 months (95% CI, 41.4-46.4).

Results showed no difference in overall survival or progression-free survival between the 2 targeted therapies, and the response rate was similar in both groups.

Overall survival was 20.1 months (95% CI, 18.76-21.42) with sunitinib compared with 23.68 months (95% CI, 19.54-28.81) with pazopanib (HR, 0.952; 95% CI, 0.788-1.150; P = .61). Progression-free survival was 7.22 months (95% CI, 6.76-7.78) and 6.83 months (95% CI, 5.58-8.27), respectively (HR, 1.052; 95% CI, 0.908-1.220; P = .49).

“We found no difference in response rate between first-line sunitinib and pazopanib,” said José Manuel Ruiz-Morales, MD, of the Tom Baker Cancer Centre in Calgary, Canada, during the poster presentation.

RELATED: Debate: Does Ischemia Still Matter During Partial Nephrectomy?

In comparison, the COMPARZ study demonstrated that pazopanib was noninferior to sunitinib in terms of progression-free survival and had similar overall survival.2

“Recent data on the individualization of sunitinib dosing is not captured in this study and is a subject of future investigation,” Dr. Ruiz-Morales noted.

Reference

  1. Ruiz-Morales JM, Wells JC, Donskov F, et al. First line sunitinib versus pazopanib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium [abstract]. BJU Int. 2015. doi: 10.1111/bju.13365.
  2. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722-731.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters